- The trend backdrop is active with a 9-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
INMB
NASDAQ
Week ended 11 Sep 2026
Weekly Investor Report
INmune Bio Inc · Healthcare · Biotechnology
Latest close
2.22 USD
-9.0%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 38.9% above the Trend Line and sits at 74.8% of its 52-week range. The latest completed week returned -9.0%, after a 2.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 56/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 40d.
Setup score
55
out of 100
Latest Close
2.22 USD
11 Sep 2026
1W Return
-9.0%
latest completed week
4W Return
2.3%
short-term follow-through
12W Return
53.1%
quarterly tape
Trend Breadth
17.3%
9 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 42.21% based on similar historical setup states.
- The latest week was a sharp negative move.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-9.0%
Latest completed week; four-week move 2.3%.
Indicator stack
41/79
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.21%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
56/100 conviction; expected move 18.7%.
News sentiment
50/100
7 relevant articles in the latest sentiment read.
Event risk
40d
Next report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 38.9% above the Trend Line and sits at 74.8% of its 52-week range. The latest completed week returned -9.0%, after a 2.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7012-week average 0.32
12-week confirmation
Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.70Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
4 accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 2.3% over four weeks, 53.1% over 12 weeks, and 10.4% over one year. The current trend has remained active for 9 consecutive weeks.
Performance by holding period
Active trend streak9 weeks
Active weeks in one year9
Trend breadth17.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.55Latest activity-pressure read.
Pressure change12.9%Four-week change in activity pressure.
Leadership21.35Latest relative-leadership reading.
RS change46.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 11 Sep 2026
Financial statements through 30 Jun 2026
Field coverage 67%
Model confidence 67%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength71/100Blend of value, momentum, and quality. Underlying universe rank 30; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -36.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -451.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 257.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.9% Net share repurchases relative to market value.
- Shareholder yield
- -0.9% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
INMB shows volatility options pressure with a 56/100 conviction score, put-call volume ratio of 0.00, expected move of 18.7%, and Sharemaestro trend signal active.
Conviction56/100
Expected move18.7%
Put/call volume0.00
Insider activity3 / 3
3 acquisitions and 3 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment50/100
Weighted news tone is neutral across 7 relevant articles.
1 positive · 6 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings40dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
Options expected move18.7%Nearest-chain priced movement where available.
52-week drawdown-14.6%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
20 Mar
17 Apr
15 May
12 Jun
10 Jul
7 Aug
11 Sep
Weeks higher13 of 2613 weeks finished lower.
Best week+22.9%Week of 17 Apr.
Worst week-14.7%Week of 24 Jul.
Latest week-9.0%Week of 11 Sep.
Shape of recent returns
Strong gains12
Modest gains1
Flat weeks0
Modest losses5
Sharp losses8
Recent vol10.2%13-week weekly-return volatility.
Base vol9.1%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew9.5% / -6.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average0.6%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD69.0%positive activity pressure
RS53.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-0.7%
Trend breadth76.0%
Trend76.0%active weekly trend signals
MD69.0%positive activity pressure
RS61.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape50/100
Trend, activity pressure, participation, and risk combine to a 50/100 tape read.
Indicator analysis76/100Latest 12-week confirmation: trend 9/12, activity pressure 12/12, relative leadership 6/12.
Activity pressure 0.70; No reversal markers Next-Week ExpectancyNegative 42.21%Next-week expectancy is negative with a 42.21% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors62/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 87; Small Cap Core rank 46 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options40/100INMB shows volatility options pressure with a 56/100 conviction score, put-call volume ratio of 0.00, expected move of 18.7%, and Sharemaestro trend signal active.
Volatility · Volatility expansion watch · Expected move 18.7% Sentiment50/100Weighted news tone is neutral across 7 relevant articles.
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board Insiders3 / 33 acquisitions and 3 disposals in the latest 180-day insider tape.
Earnings40dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | 2.22 USD | -9.0% | 1.60 USD | 5.62 USD | 1.55 | 21.35 | 1.3M | On |
| 4 Sep 2026 | 2.44 USD | 4.7% | 1.57 USD | 5.66 USD | 1.58 | 32.29 | 1.1M | On |
| 28 Aug 2026 | 2.33 USD | 0.4% | 1.54 USD | 5.70 USD | 1.58 | 26.77 | 1.7M | On |
| 21 Aug 2026 | 2.32 USD | 6.9% | 1.52 USD | 5.74 USD | 1.50 | 26.45 | 1.8M | On |
| 14 Aug 2026 | 2.17 USD | 4.1% | 1.50 USD | 5.77 USD | 1.38 | 14.59 | 1.9M | On |
| 7 Aug 2026 | 2.08 USD | 19.1% | 1.48 USD | 5.81 USD | 1.41 | 10.15 | 2.3M | On |
| 31 Jul 2026 | 1.75 USD | 8.0% | 1.46 USD | 5.85 USD | 1.47 | -3.96 | 888.8K | On |
| 24 Jul 2026 | 1.62 USD | -14.7% | 1.45 USD | 5.89 USD | 1.55 | -11.94 | 1.8M | On |
| 17 Jul 2026 | 1.90 USD | -2.1% | 1.46 USD | 5.94 USD | 1.68 | -0.11 | 4.6M | On |
| 10 Jul 2026 | 1.94 USD | 14.1% | 1.46 USD | 5.98 USD | 1.54 | -3.34 | 6.0M | Off |
| 3 Jul 2026 | 1.70 USD | 19.7% | 1.46 USD | 6.04 USD | 1.29 | -14.65 | 3.6M | Off |
| 26 Jun 2026 | 1.42 USD | -2.1% | 1.47 USD | 6.09 USD | 1.14 | -29.16 | 16.7M | Off |
| 19 Jun 2026 | 1.45 USD | 16.9% | 1.48 USD | 6.14 USD | 1.01 | -34.37 | 1.1M | Off |
| 12 Jun 2026 | 1.24 USD | -1.6% | 1.48 USD | 6.19 USD | 1.00 | -45.93 | 1.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.